Skip to main content

Webinar: The Next Generation of AAV characterization Tools

Webinar Summary

In this webinar, join Tony Bou Kheir, PhD, from the Cell and Gene Therapy Catapult in London, as he showcases the Cell and Gene Therapy Catapult's adeno-associated viruses (AAV) analytical platform and advantages it offers to current industry standards.

Adeno-associated viruses (AAV) are increasingly popular in gene therapy due to their mild immune response, ability to infect a broad range of cells, and overall safety (Naso et al., 2017). Due to the complexity of the delivery vector, a series of robust analytical approaches are required to ensure correct assembly and packaging prior to product release. As the gene therapy field continues to expand and companies increase the number of product batches manufactured per year, the burden on quality control for product release increases significantly. The Cell and Gene Therapy Catapult developed an advanced analytical platform for AAV vector characterization, addressing industry challenges in 1) assay precision through implementation of next generation technologies, 2) standardization and throughout through automation, and 3) enabling in-line product characterization in closed processes through the development of process analytical technologies.


Tony Bou Kheir, PhD, Lead Technical Scientist, Cell and Gene Therapy Catapult - London

Chris Heger, Ph.D., Senior Manager, Applications Science - Bio-Techne